Business Wire
26 Jun 2026, 10:49 UTC · 3h ago
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Business Wire
26 Jun 2026, 10:49 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
The EMA's CHMP has issued a positive opinion recommending marketing authorization for DAYBU (trofinetide) for Rett syndrome in adults and children aged five and older. — Positive regulatory opinions from the EMA significantly increase the probability of product launch and future revenue streams in the European market.
+0.80Which stocks this story touches
The EMA's CHMP issued a positive opinion recommending marketing authorization for its drug DAYBU for Rett syndrome.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
7h ago
